Cargando…

Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature

Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) is a universal event and limits clinical efficacy. The third-generation EGFR inhibitor osimertinib is active in EGFR-mutant/T790M positive non-small-cell lung cancer. Mechanisms of acquired resistance are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klempner, Samuel J, Mehta, Pareen, Schrock, Alexa B, Ali, Siraj M, Ou, Sai-Hong Ignatius
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723122/ https://www.ncbi.nlm.nih.gov/pubmed/29255376 http://dx.doi.org/10.2147/LCTT.S147129

Ejemplares similares

EGFR G796D mutation mediates resistance to osimertinib
por: Zheng, Di, et al.
Publicado: (2017)

Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification
por: Zhu, Viola W, et al.
Publicado: (2019)

Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, cis-G796s/cis-C797s by osimertinib, brigatinib, and bevacizumab combination therapy: A case report
por: Chang, Yuan, et al.
Publicado: (2022)

NGS-Based ctDNA Profiling After the Resistance of Second-Line Osimertinib for Patient with EGFR-Mutated Pulmonary Adenocarcinoma
por: Li, Dan, et al.
Publicado: (2021)

EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome
por: Vendrell, Julie A., et al.
Publicado: (2021)

Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
por: Zhang, Shannon S, et al.
Publicado: (2022)

Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib
por: Wang, Yubo, et al.
Publicado: (2022)

A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review
por: Zhu, Viola W., et al.
Publicado: (2020)

Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy
por: Kallergi, Galatea, et al.
Publicado: (2022)

Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2017)

Effective clinical response of lung adenocarcinoma harboring EGFR 19Del/T790M/in cis-C797S osimertinib to osimertinib and gefitinib combination therapy
por: Wang, Yanyan, et al.
Publicado: (2023)

Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation
por: Zhu, Viola W, et al.
Publicado: (2018)

Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab
por: Lopez, Michael, et al.
Publicado: (2023)

ORIENT-31 as the Sakigake “Charging Samurai” Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the “Meiji Modernization” of Post-3G EGFR TKI Progression?
por: Nagasaka, Misako, et al.
Publicado: (2022)

Identification of the ABO*cis-AB04 Allele With a Unique Substitution C796A: The First Case in Korea
por: Yoon, Jung, et al.
Publicado: (2016)

Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report
por: Crowley, Fionnuala, et al.
Publicado: (2021)

ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib
por: Romero, Atocha, et al.
Publicado: (2020)

In Response to Dr. Steven Sorscher
por: Zhang, Shannon S., et al.
Publicado: (2022)

Treatment of Choroidal Metastasis from Epidermal Growth Factor Mutant Non-Small Cell Lung Cancer with First-line Osimertinib Therapy
por: N. Vu, Anderson, et al.
Publicado: (2022)

A strategy to overcome EGFR p.T790M cis p.L792F induced resistance to osimertinib
por: Malapelle, Umberto, et al.
Publicado: (2022)

Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs
por: Zhang, Chengjuan, et al.
Publicado: (2017)

Successful Treatment of EGFR-Mutant Synchronous SCLC and Lung Adenocarcinoma With Osimertinib
por: Batra, Ullas, et al.
Publicado: (2020)

Combination of Osimertinib and Anlotinib May Overcome the Resistance Mediated by in cis EGFR T790M-C797S in NSCLC: A Case Report
por: Zhou, Rengui, et al.
Publicado: (2021)

Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments
por: Denis, Marc G, et al.
Publicado: (2020)

Co‐mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer
por: Xing, Puyuan, et al.
Publicado: (2019)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

EGFR Testing Patterns and Detection of EGFR Exon 20 Insertions in the United States
por: Lin, Huamao M., et al.
Publicado: (2022)

796 Transmission of Human Rhinovirus Genotypes among Childcare Attendees
por: Martin, Emily K., et al.
Publicado: (2014)

796. Treatment of Latent Tuberculosis Infection in a Refugee Population
por: Herchline, Thomas, et al.
Publicado: (2018)

A High Percentage of NSCLC With Germline CHEK2 Mutation Harbors Actionable Driver Alterations: Survey of a Cancer Genomic Database and Review of Literature
por: Zhang, Shannon S., et al.
Publicado: (2022)

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020)

Is there a role for sequential afatinib and osimertinib in patients with EGFR mutation?
por: Iwamoto, Natsuhiko, et al.
Publicado: (2022)

Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
por: Lee, Jiyun, et al.
Publicado: (2022)

Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2015)

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
por: Imamura, Fumio, et al.
Publicado: (2020)

Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial
por: Cho, Byoung Chul, et al.
Publicado: (2023)

Moving the Needle Cautiously in Targeting One of the Most Often Acquired Receptor Tyrosine Fusion (RET Fusion) Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors
por: Zhang, Shannon S., et al.
Publicado: (2022)

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
por: Murano, Chihiro, et al.
Publicado: (2019)

Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0akku20gstljldvr2jlhgt9r6h